The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
4-(4-(4-methoxyphenyl)phthalazin-1-ylamino)benzenesulfonamide ID: ALA5208678
PubChem CID: 17129179
Max Phase: Preclinical
Molecular Formula: C21H18N4O3S
Molecular Weight: 406.47
This compound is available for customization.
Associated Items:
Names and Identifiers Canonical SMILES: COc1ccc(-c2nnc(Nc3ccc(S(N)(=O)=O)cc3)c3ccccc23)cc1
Standard InChI: InChI=1S/C21H18N4O3S/c1-28-16-10-6-14(7-11-16)20-18-4-2-3-5-19(18)21(25-24-20)23-15-8-12-17(13-9-15)29(22,26)27/h2-13H,1H3,(H,23,25)(H2,22,26,27)
Standard InChI Key: YZFSGMLQROGKMX-UHFFFAOYSA-N
Molfile:
RDKit 2D
29 32 0 0 0 0 0 0 0 0999 V2000
-0.7731 3.9173 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-0.7731 3.0923 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.0566 2.6833 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.0566 1.8588 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.7742 1.4446 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.4877 1.8572 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.4877 2.6797 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.7742 0.6196 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.0576 0.2072 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-0.0576 -0.6136 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-0.7691 -1.0301 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.7691 -1.8551 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-0.0546 -2.2675 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.0546 -3.0960 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.6617 -3.5042 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.3718 -3.0923 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.0863 -3.5049 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
2.4996 -2.7908 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
2.9127 -3.5049 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
2.0863 -4.3298 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1.3718 -2.2671 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.6599 -1.8552 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.4867 -0.6161 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.1965 -1.0278 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.9127 -0.6198 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.9127 0.2084 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.1983 0.6206 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.4867 0.2088 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.4875 4.3298 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2 1 1 0
3 2 1 0
4 3 2 0
5 4 1 0
6 5 2 0
7 6 1 0
2 7 2 0
8 5 1 0
9 8 2 0
10 9 1 0
11 10 2 0
11 12 1 0
12 13 1 0
13 14 1 0
14 15 2 0
15 16 1 0
16 17 1 0
17 18 2 0
17 19 2 0
17 20 1 0
16 21 2 0
21 22 1 0
22 13 2 0
23 11 1 0
24 23 1 0
25 24 2 0
26 25 1 0
27 26 2 0
28 27 1 0
28 8 1 0
23 28 2 0
1 29 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Topical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 406.47Molecular Weight (Monoisotopic): 406.1100AlogP: 3.70#Rotatable Bonds: 5Polar Surface Area: 107.20Molecular Species: NEUTRALHBA: 6HBD: 2#RO5 Violations: ┄HBA (Lipinski): 7HBD (Lipinski): 3#RO5 Violations (Lipinski): ┄CX Acidic pKa: 10.74CX Basic pKa: 3.07CX LogP: 3.28CX LogD: 3.28Aromatic Rings: 4Heavy Atoms: 29QED Weighted: 0.52Np Likeness Score: -1.33
References 1. Lee SY, Namasivayam V, Boshta NM, Perotti A, Mirza S, Bua S, Supuran CT, Müller CE.. (2021) Discovery of potent nucleotide pyrophosphatase/phosphodiesterase3 (NPP3) inhibitors with ancillary carbonic anhydrase inhibition for cancer (immuno)therapy., 12 (7.0): [PMID:34355184 ] [10.1039/D1MD00117E ] 2. Ahmad, Haseen and 7 more authors. 2020-12-15 Synthesis of biphenyl oxazole derivatives via Suzuki coupling and biological evaluations as nucleotide pyrophosphatase/phosphodiesterase-1 and -3 inhibitors. [PMID:32883636 ]